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Abstract
Background: Parkinson’s disease (PD) is a slowly progressive neurodegenerative disorder which affects widespread
areas of the brainstem, basal ganglia and cerebral cortex. A number of proteins are known to accumulate in
parkinsonian brains including ubiquitin and a-synuclein. Prion diseases are sporadic, genetic or infectious disorders
with various clinical and histopathological features caused by prion proteins as infectious proteinaceous particles
transmitting a misfolded protein configuration through brain tissue. The most important form is Creutzfeldt-Jakob
disease which is associated with a self-propagating pathological precursor form of the prion protein that is
physiologically widely distributed in the central nervous system.
Discussion: It has recently been found that a-synuclein may behave similarly to the prion precursor and
propagate between cells. The post-mortem proof of a-synuclein containing Lewy bodies in embryonic dopamine
cells transplants in PD patient suggests that the misfolded protein might be transmitted from the diseased host to
donor neurons reminiscent of prion behavior. The involvement of the basal ganglia and brainstem in the
degenerative process are other congruencies between Parkinson’s and Creutzfeldt-Jakob disease. However, a
number of issues advise caution before categorizing Parkinson’s disease as a prion disorder, because clinical
appearance, brain imaging, cerebrospinal fluid and neuropathological findings exhibit fundamental differences
between both disease entities. Most of all, infectiousness, a crucial hallmark of prion diseases, has never been
observed in PD so far. Moreover, the cellular propagation of the prion protein has not been clearly defined and it
is, therefore, difficult to assess the molecular similarities between the two disease entities.
Summary: At the current state of knowledge, the molecular pathways of transmissible pathogenic proteins are not
yet fully understood. Their exact involvement in the pathophysiology of prion disorders and neurodegenerative
diseases has to be further investigated in order to elucidate a possible overlap between both disease categories
that are currently regarded as distinct entities.
Background
Parkinson’s disease (PD) is a sporadic or familial neuro-
degenerative disorder histopathologically characterized
by intraneuronal protein aggregates staining positive for
a-synuclein (Lewy Bodies, LB). Concomitant Alzheimer
disease type neuropathological features with amyloid
deposits and plaques are also frequently found [1]. A
recent clinico-pathological study on 242 brain donors
with pathologically verified PD showed the presence of
neurofibrillary tangles in 47% of cases with non-tremor
dominant PD, neocortical amyloid plaque formation in
62% and amyloid angiopathy in 22% [2]. Although the
cause of cell death in PD is unknown, the abnormal pro-
cessing of neuronal proteins seems to play a key role in
the pathophysiology of the disease. It has been shown
that impaired proteolytic cleavage and degradation of
misfolded proteins lead to their intracellular accumula-
tion and conglomeration as LB [3]. One of the key pro-
t e i n si nt h i sp r o c e s si sa-synuclein (SNCA). Recent in
vitro findings demonstrated that elevated levels of mis-
folded SNCA can promote its self-aggregation with amy-
loid formation [4,5]. Misfolded SNCA is also able to
spread over adjacent neurons and to induce degenerative
changes in transfected cells [4]. Moreover, two post-
mortem studies showed SNCA-positive LB in embryonic
dopamine cells of beforehand transplanted PD patients
suggesting that the microenvironment of the host brain
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transplants [6,7]. Therefore, the debate came up whether
SNCA behaves like a prion protein and PD might be a
prion-like disease [8], which opens up an exciting new
perspective on the pathomechanisms of neurodegenera-
tive diseases in general. However, it has to be kept in
mind that PD is neither infectious nor has it been trans-
mitted to laboratory animals. The aim of this paper is to
summarize important pros and cons of the prion hypoth-
esis of PD.
Discussion
Molecular biology of prion diseases
Prion proteins (PrP) are infectious proteinaceous parti-
cles devoid of nucleic acids causing animal and human
brain diseases by transmitting a misfolded protein con-
figuration through brain tissue [9]. The cellular prion
protein (PrP
C) is the endogenous and physiological form
with a predominant a-helix structure, which can be
found on cell membranes of many tissues. In contrast,
the prion protein scrapie (PrP
Sc)i s o f o r m ,w h i c hi s
encoded by the chromosomal prion protein gene
(PRNP), is an infectious agent with a much higher pro-
portion of b- s h e e ts t r u c t u r ea n das t r o n gt e n d e n c yt o
aggregate in form of amyloid fibers and plaques [10].
PrP
Sc is able to convert normal PrP
c into the infectious
PrP
Sc by a conformation change from a-helix to b-sheet
structure, which is considered the key event underlying
prion diseases [9]. In this scenario, PrP
Sc acts like a tem-
plate for the conversion of PrP
c into nascent PrP
Sc con-
stituting a self-propagating vicious cycle [11]. Prion
diseases can be basically caused by three pathogenic
mechanisms: 1. sporadic configuration change from PrP
c
to PrP
Sc, 2. genetic origin by mutations in the PRNP
gene and 3. transfection of PrP
Sc and subsequent con-
version of PrP
c by the ingested pathogen. The accumu-
lation and limited proteolysis of PrP
Sc leads to the small
molecule PrP27-30 which polymerizes into amyloid
potentially capable of inducing neurodegenerative
changes in brain tissue [12]. Prion diseases manifest as
sporadic, genetic or infectious disorders with a variety of
clinical symptoms and histopathological findings. The
most common form is sporadic Creutzfeld-Jakob disease
(CJD) with an incidence of nearly 5 per 1 million among
individual between 60 and 74 years of age [13]. CJD is
histopathologically characterized by spongiform brain
degeneration and astrogliosis with amyloid plaques and
positive antibody staining against PrP
Sc in about 10 per-
cent of cases [14,15].
Molecular biology of alpha-synuclein (SNCA)
Several lines of evidence point to the outstanding
importance of SNCA for PD pathophysiology. SNCA
has been shown to be a major component of LB as the
pathological hallmark of PD patients containing charac-
teristic protein aggregates in widespread brain areas
[16,17]. Mutations of the SNCA encoding gene are asso-
ciated with familial forms of PD [18]. Increased intracel-
lular SNCA levels can arise from duplication or
triplication of the wild-type protein in familial cases
[19,20] or from impaired lysosomal and proteasomal
clearance of the protein in sporadic PD [21]. Moreover,
previous data documented neuronal degeneration by the
inhibition of proteasomal protein degradation and sub-
sequent inclusion formation [22]. Other potentially toxic
effects of SNCA are the induction of endoplasmatic reti-
culum stress, sequestration of anti-apoptotic proteins
and the formation of pores in cellular membranes [23].
Arguments for a prion-like pathogenesis in PD
The prion-like disease hypothesis of PD is particularly
based upon striking parallels in the biological properties
and behavior of PrP
Sc a n dS N C A .T h ef i r s to n ei st h a t
both have
a-helical rich conformation when bound to mem-
branes and that both undergo a change to b-sheet struc-
ture polymerizing into amyloid fibrils when present in
high concentration or in mutant form [24,25]. The sec-
ond important similarity is that misfolded SNCA also
promotes a self-propagating conformation change of its
physiological alpha-helical isomer leading to potentially
toxic protein accumulation and to interference with lyso-
some and proteasome function [5]. The third important
parallel between SNCA and PrP
Sc is that both reveal a
kind of transmissibility. While the infectious nature of
spongiform encephalopathies is undoubtedly proven, a
recent pathbreaking study demonstrated that SNCA can
be directly transferred from SNCA overexpressing neu-
rons to adjacent healthy stem cells in transgenic animals
with the subsequent development of inclusion bodies and
signs of neuronal degeneration [4]. Direct cell-to-cell
propagation of SNCA was mediated by endocytosis of
recipient cells. SNCA accumulated when lysosomes in
recipient cells were inhibited. The donor-derived SNCA
formed juxta-nuclear inclusion bodies and recipient cells
showed signs of apoptosis (nuclear fragmentation, cas-
pase-3 activation). A further line of evidence comes from
two recent post-mortem studies showing SNCA-positive
LB in embryonic dopamine cells of PD patients who had
been transplanted over ten years ago [6,7]. Since the
appearance of LB has never been described in embryonic
neurons before, it is very likely that the microenviron-
ment of the diseased host brain led to the development
of SNCA-positive aggregates in the transplants. One pos-
sible explanation for this finding is that misfolded SNCA
is transmitted from the affected host to primarily healthy
donor neurons inducing the fatal chain reaction of
further protein misfolding.
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Braak and colleagues has attracted enormous attention
[26]. It assumes that a currently unknown pathogen
enters the central nervous system via the olfactory
epithelium and enteric nerves and reaches the olfactory
bulb and the dorsal motor nucleus of the vagal nerve via
antero- and retrograde transport. In later disease stages,
the process spreads in a sequential ascending manner
particularly in neurons rich of native SNCA, such as the
enthorhinal cortex, hippocampus, amygdala, substantia
nigra, insula and temporo-basal cortex. The hypothesis
that misfolded SNCA acts like a prion with sequential
cell-to-cell transmission offers an attractive explanation
of Braak’s findings. These are indeed compatible with the
view of PD as a prion-like disorder resulting from
increased production or insufficient degradation of toxic
SNCA. In this scenario, the abnormal conversion of
native to b-sheet SNCA might be triggered or supported
by various drivers, such as hereditary factors, aging, oxi-
dative stress or environmental toxins.
Finally, the similarity of genetic forms of PD and prion
diseases is noticeable. The inherited forms of prion dis-
eases base on different mutations in the prion protein
gene (PRNP) on chromosome 20, which are associated
with various clinical phenotypes and responsible for
about 10-15% of prion disorders [27]. At the protein
level, the encoded mutated PrPs seem to fold into differ-
ent pathogenic conformers accounting for the phenoty-
pic variability [28]. The E200K mutation is the most
prevalent one worldwide with autosomal-dominant
inheritance and incomplete penetrance leading to a
genetic form of CJD with rapidly progressive dementia
and myoclonus along with pyramidal, cerebellar and
extrapyramidal signs [29]. Just like prion disease, most
PD cases are sporadic, but also several inherited mono-
genetic PD forms were identified over the last decade
[30]. The first reported were autosomal-dominant muta-
tions of the SNCA gene on the long arm of chromo-
some 4 (PARK1) [18]. Similar to mutated PrPs, amino-
acid changes in the SNCA encoded protein presumably
leads to an increased tendency for intracellular aggregate
formation [31]. Multiplications of the wildtype SNCA
gene have been shown to induce higher SNCA blood
levels [32] and to cause familial parkinsonism [20].
Although the exact physiological properties of wild-type
SNCA and PrP are not yet completely understood, a
gain-of-function of the mutated protein with certain
importance for the neurodegenerative process in PD
and in prion diseases is likely in both (see [33,34] for
detailed reviews). Transgenic (PG14-EGFP) mice
develop an ataxic neurological disease with aggregation
of a partially protease-resistant mutant PrP [35]. A simi-
lar disease process has been demonstrated in mouse
prion promoter (mPrP) A53T SNCA transgenic mice,
which revealed SNCA aggregation and progressive age-
dependent neurodegeneration [36,37].
Arguments against a prion-like pathogenesis in PD
CJD is a rapidly progressive disease associated with a
self-propagating pathological prion protein. The life
cycle of a prion includes synthesis in the endoplasmic
reticulum of many cell types in- and outside the brain,
transport to the external cellular membrane, secretion
and trans-synaptic transport to neighbouring neurons
and astrocytes, re-entry into the cell and degredation in
the lysosomal apparatus. Prion proteins travel large dis-
tances systemically in the blood stream carried by lym-
phocytes and through the central nervous system along
axons that can be more than one meter in length [38].
Concerning neuropathological similiarities between CJD
and PD, it is important to consider which specific fea-
tures of prion replication are actually mimicked by
SNCA.
Many disease processes, such as Alzheimer’s and Hun-
tington disease, cerebellar ataxias or serpinopathies,
include the accumulation of a pathological protein, an
initiation “seed” of protein aggregation, stable protein
aggregates, diffusion of the pathological protein and the
potential for the pathological protein to cause cell
damage leading in turn to enhanced protein accumula-
tion. It is not absolutely clear how SNCA directly causes
propagation of its abnormal form. As in prion pathol-
ogy, it has been hypothesized that a direct interaction
exists between the pathological beta pleated sheet and
the normal alpha coil form leading the latter to be
transformed into pathological aggregates [8]. However,
even in the classical PrP associated prion diseases the
exact mechanism of propagation has not been clearly
defined or replicated under physiological cell free condi-
tions. In addition, prion accumulation in cell cultures
does not seem to have the same detrimental effects, for
example apoptosis, which can be observed in cultures
exposed to pathological SNCA. Therefore, it is currently
hardly to argue that these processes are significantly
similar.
From a clinical point of view, CJD and PD are very
different diseases. While PD has a slow but continuously
progressive course, CJD remains latent for many years
followed by a rapid and exponentially devastating phase
that ends within a few months. Typical clinical manifes-
tations of CJD, such as early occurring dementia, ataxia
and myoclonus, are usually not found in PD. CJD
patients have typical EEG findings, for example triphasic
waves or periodic lateralized epileptic discharges, and a
characteristic increase of tau and 14-3-3 protein in the
CSF, which are absent in PD. A recent cross-sectional
study in patients with various neurodegenerative dis-
eases has performed direct ELISA quantification of
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significantly lower in donors with a primary synucleino-
pathy (PD, Dementia with Lewy Bodies) than in the
other study subgroups, whereas CJD patients showed
markedly elevated SNCA levels. Magnetic resonance
imaging often reveals hyperintense lesions in the basal
ganglia and the thalamus of CJD patients, which are
lacking in PD. Furthermore, spongiform encephalopathy
as the pathological hallmark of CJD is not a feature of
PD, whereas LB are not present in CJD. Infectiousness
is a crucial hallmark of prion diseases, which can mani-
fest after iatrogenic procedures such as neurosurgical
operations as well as corneal and dural transplantations
[40], whereas this kind of transmission has never been
documented in PD patients so far. Finally, disease modi-
fying substances have been found in PD animal models
in vitro, while no such agents are currently available for
CJD.
Summary
The prion-like hypothesis of PD implies a redefinition of
the term prion away from its exclusive use in transmis-
sible spongiform encephalopathies towards a general
infectious principle in protein misfolding and aggrega-
tion diseases. It focuses the researchers’ attention on the
k e yr o l eo fS N C Am a l f u n c t i o ni nt h ep a t h o g e n e s i so f
PD and implies that blocking the mishandling of SNCA
and other proteins might be an effective therapeutic
strategy in PD patients. However, at the current state of
knowledge, a number of issues advise caution before
categorizing PD as a prion disorder, because the mole-
cular pathways of transmissible pathogenic proteins are
not yet fully understood and clinical, brain imaging, CSF
and neuropathological findings clearly differ in patients
with classic prion diseases and PD.
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